NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/26/2026
Back to search
Official data from USPTO
TG THROMBOGENICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
02/27/2026
Trademark type
Combined
Nice classes
1, 5, 42, 44
Filing date
11/30/2010
Registration date
11/01/2011
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/13/2022
Last transaction
02/27/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
BE
Examiner
RUTLAND, BARBARA A
Law office
L10
Mark description
The mark consists of the letters "TG" in grey and the word "thrombogenics" in red with a grey vertical line separating the literal elements of the mark.
Holders and representatives
Holders
Oxurion NV
ThromboGenics NV
Representatives
Thomas J. Mango Cantor Colburn LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical preparations and substances for use in the manufacture of pharmaceuticals
Class 5
Pharmaceutical preparations for treatment of diseases and disordersophthalmic and visual disordersvascular and cardiovascular disorderscardiac diseasesstrokeinflammationhypertensionpulmonary hypertensionedemaimmune system disordersimmune system related disorderseye diseasesblood disordersthrombotic diseases and cancer; veterinary preparations for treatment of diseases and disorders in mammaliansophthalmic and visual disordersvascular and cardiovascular disorderscardiac diseasesstrokeinflammationhypertensionpulmonary hypertensionedemaimmune system disordersimmune system related disorderseye diseasesblood disordersthrombotic diseases and cancer; sanitary preparations for medical purposes; dietetic foods adapted for medical usefood for babies; medical plasters; material for stopping teethdental wax; disinfectants for medical instrumentsfor hygienic purposesfor use in medical surgery procedures; preparations for destroying vermin; fungicidesherbicides; biopharmaceutical preparationsanticoagulantsanti angiogenic drugsanticancer drugscardiovascular drugsprotease enzymesprotease inhibitorsantibodiesplasminstruncated plasminsmicroplasminsplasminogenstruncated plasminogensmicroplasminogensplasminogen activatorsstaphylokinases for the treatment diseases and disordersophthalmic and visual disordersvascular and cardiovascular disorderscardiac diseasesstrokeinflammationhypertensionpulmonary hypertensionedemaimmune system disordersimmune system related disorderseye diseasesblood disordersthrombotic diseases and cancer; diagnostic medical reagentschemicals and biological materialsantigen and diagnostic kits consisting primarily of monoclonal and/or polyclonal antibodiesbuffersreagents for medical laboratory use in disease testing
Class 42
Scientific and technological servicesscientific research and design of new products in the field of ophthalmicvisualvascularcardiacinflammationhypertensionimmune systemblood and cancer disease and disorder detectionin the field of ophthalmicvisualvascularcardiacinflammationhypertensionimmune systemblood and cancer disease and disorder preventionin the field of ophthalmicvisualvascularcardiacinflammationhypertensionimmune systemblood and cancer disease and disorder treatment; industrial analysis and product research services in the field of ophthalmicvisualvascularcardiacinflammationhypertensionimmune systemblood and cancer disease and disorder detectionin the field of ophthalmicvisualvascularcardiacinflammationhypertensionimmune systemblood and cancer disease and disorder prevention and in the field of ophthalmicvisualvascularcardiacinflammationhypertensionimmune systemblood and cancer disease and disorder treatment; pharmaceuticalbiopharmaceuticalmedicalbiomedicalbiologicalbiochemicaltoxicological and clinical research and product development of diagnostic tests and kitsbiopharmaceutical preparations and drugsmedicines; biopharmaceutical product evaluation; biologicalbiochemicalpharmaceuticalmedicaltoxicological and clinical researchscientific research for medical purposes in the treatment of ophthalmicvisualvascularcardiacinflammationhypertensionimmune systemblood and cancer diseases and disorders; development services in the field of new biopharmaceutical drugspreparations and medicines for ophthalmicvascular and cancer pathologies
Class 44
Medical services; veterinary services; medicalveterinary and pharmaceutical advisory and consultancy services; medical servicestherapeuticprognostic and diagnostic testing services
Publications
History of USPTO decisions and trademark events.
42 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/08/2026
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
04/11/2023
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
03/01/2023
INPC
INVALIDATION PROCESSED
03/01/2023
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
01/13/2023
C71T
CANCELLED SECTION 71
05/13/2022
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/17/2020
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
11/01/2020
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
06/13/2019
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
03/08/2019
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
01/26/2019
INPC
INVALIDATION PROCESSED
01/26/2019
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
01/11/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/28/2018
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
05/11/2018
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
05/11/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/11/2018
ES71
TEAS SECTION 71 RECEIVED
05/01/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/28/2012
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/08/2012
FIMP
FINAL DISPOSITION PROCESSED
06/08/2012
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/01/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2011
PUBO
PUBLISHED FOR OPPOSITION
08/16/2011
NPUB
NOTICE OF PUBLICATION
07/27/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/13/2011
ALIE
ASSIGNED TO LIE
07/12/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/18/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/17/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/17/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/17/2011
RFNT
REFUSAL PROCESSED BY IB
04/09/2011
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/22/2011
RFRR
REFUSAL PROCESSED BY MPU
03/22/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/19/2011
CNRT
NON-FINAL ACTION WRITTEN
03/18/2011
MAFR
APPLICATION FILING RECEIPT MAILED
03/12/2011
DOCK
ASSIGNED TO EXAMINER
03/08/2011
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/08/2011
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/04/2011
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/03/2011
Continuous trademark protection
Get notified about every new filing that threatens TG THROMBOGENICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.